Talquetamab and Its Effect on Relapsed and Refractory Multiple Myeloma.
Relapsed and refractory multiple myeloma (RRMM) remains a challenging condition despite many advances in immunotherapies. Talquetamab demonstrated a high overall response rate of approximately 70%, including in patients that are previously treated with T-cell therapies.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Dual Metabolic Inhibition Via Vanadium-NO Synergistic Nanoplatform…
Immunotherapy has emerged as a pivotal strategy in cancer treatment. Collectively, this study establishes a nanoplatform centered on multi-metabolic regulation, which may hold potential for further preclinical evaluation as a strategy to enhance cancer immunotherapy.
Standard additionA novel multiplex digital PCR assay for simultaneous quantification…
Somatic androgen receptor (AR) alterations including gene amplification, point mutations, and the AR-V7 splice variant occur in 50-70% of patients with metastatic castration-resistant prostate cancer (mCRPC) and drive resistance to AR-pathway inhibitors (ARPIs) in metastatic castration-resistant prostate cancer (mCRPC). This multimodal dPCR platform provides a cost-effective, highly sensitive liquid biopsy tool for detection of clinically significant AR alterations and represents a foundation for a laboratory-developed test (LDT) to guide personalized therapy in mCRPC.
Underserved or high-risk populationsSurgical Treatment of Tumor-Induced Osteomalacia With Causative…
This study aimed to investigate and summarize the clinical features and surgical outcomes of TIO patients with culprit tumors involving the long bones to enhance clinical understanding and improve orthopedic surgical management of this rare disease. The actual clinical application effect of this classification system needs further clinical data verification.
Standard additionImpact of Physical Activity on Cardiovascular Outcomes in Metabolic…
We investigated whether accelerometer-assessed moderate-to-vigorous physical activity (MVPA) is associated with cardiovascular mortality among individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) in the United States. Higher MVPA is nonlinearly associated with cardiovascular mortality in individuals with MASLD.